Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder

Objective To determine if changes in chromosome 7 and 17 copy number can be used to predict recurrence in patients with primary noninvasive (pTa) or superficially invasive (pT1) transitional cell carcinoma (TCC) of the urinary bladder.

[1]  K. Grigor,et al.  Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? , 1998, British Journal of Cancer.

[2]  K. Lam.  Application of 'one-bead one-compound' combinatorial library method for cancer research and drug discovery , 1998 .

[3]  D. Neal,et al.  Molecular biological changes in bladder cancer. , 1998, Cancer surveys.

[4]  E. Messing,et al.  Bladder cancer: natural history, tumor markers, and early detection strategies. , 1997, Seminars in surgical oncology.

[5]  J. Hofbauer,et al.  Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. , 1997, The Journal of urology.

[6]  M. Pericak-Vance,et al.  REPORT on the Fifth International Workshop on Chromosome 9 held at Eynsham, Oxfordshire, UK, September 4–6, 1996 , 1997, Annals of human genetics.

[7]  M. Igawa,et al.  Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization. , 1996, British journal of urology.

[8]  M. Parmar,et al.  The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. , 1996, The Journal of urology.

[9]  H. Aburatani,et al.  Papillary Renal Cell Carcinoma: Quantitation of Chromosomes 7 and 17 by FISH, Analysis of Chromosome 3p for LOH, and DNA Ploidy , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[10]  T C Gasser,et al.  Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. , 1995, Cytometry.

[11]  M. Knowles.  Molecular genetics of bladder cancer. , 1995, British journal of urology.

[12]  J. Bartlett,et al.  C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? , 1995, Cancer research.

[13]  P. Carroll,et al.  Chromosome‐9 loss detected by fluorescence in situ hybridization in bladder cancer , 1995, International journal of cancer.

[14]  S. Devries,et al.  Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization , 1995, Genes, chromosomes & cancer.

[15]  E. Mallon,et al.  Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ , 1995, International journal of cancer.

[16]  S. Povey,et al.  REPORT on the Third International Workshop on Chromosome 9 , 1994 .

[17]  P. Carroll,et al.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. , 1994, The American journal of pathology.

[18]  A. Sandberg,et al.  Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. , 1994, The Journal of urology.

[19]  M. McCredie,et al.  Bladder and kidney cancers. , 1994, Cancer Surveys.

[20]  B H Mayall,et al.  Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. , 1991, Cancer research.

[21]  J. J. Martin,et al.  Transitional cell carcinoma of the bladder. , 1979, Rocky Mountain medical journal.